Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31413647 | 0.84 | CYP3A4 (0.45) | CYP3A4ALOX15SMN1; SMN2CASP1CASP7 | |
| SCHEMBL2790363 | 0.80 | CYP3A4 (0.41) | CYP3A4ALOX15SMN1; SMN2CASP1CASP7 | |
| SCHEMBL3290476 | 0.78 | CYP3A4 (0.50) | CYP3A4ALOX15SMN1; SMN2CASP1CASP7 | |
| SCHEMBL168119 | 0.77 | CYP3A4 (0.43) | CYP3A4ALOX15SMN1; SMN2CASP1CASP7 | |
| SCHEMBL29470925 | 0.77 | PGR (0.46) | CYP3A4ALOX15SMN1; SMN2CASP1CASP7 | |
| SCHEMBL79300 | 0.77 | PGR (0.46) | CYP3A4ALOX15SMN1; SMN2CASP1CASP7 | |
| SCHEMBL10636658 | 0.77 | KCNN4 (0.42) | CYP3A4ALOX15SMN1; SMN2CASP1CASP7 | |
| SCHEMBL2202783 | 0.75 | CYP3A4 (0.53) | CYP3A4ALOX15SMN1; SMN2CASP1CASP7 | |
| SCHEMBL344167 | 0.74 | CYP3A4 (0.45) | CYP3A4ALOX15SMN1; SMN2CASP1CASP7 | |
| SCHEMBL4706664 | 0.74 | CYP3A4 (0.45) | CYP3A4ALOX15SMN1; SMN2CASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012014109-A1 | HETEROCYCLIC SULFONAMIDES AS INHIBITORS OF TRANSFER RNA SYNTHETASE FOR USE AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2012-02-02 | — | — | WO | disclosed |
| US-7884098-B2 | 2-{[5-Fluoro-2-({3-[2-(4-morpholinyl)ethyl]phenyl}amino)-4-pyrimidinyl]amino}-N-(2-hydroxyethyl)benzamide, useful in the treatment of cancer | GLAXOSMITHKLINE LLC (US) | 2011-02-08 | — | — | US | disclosed |
| US-20100016318-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-21 | — | — | US | disclosed |
| US-7625903-B2 | Anticancer agent; N-(1-methylethyl)-2-[(5-methyl-2-{[3-(4-methyl-2-oxo-1-piperazinyl)phenyl]amino}-4-pyrimidinyl)amino]benzamide | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-01 | — | — | US | disclosed |
| EP-2121637-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | Smithkline Beecham Corporation (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080182852-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | GLAXOSMITHKLINE LLC | 2008-07-31 | — | — | US | disclosed |
| WO-2008092049-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-31 | — | — | WO | disclosed |
| US-20070082898-A1 | 5 Amino-2-carbonylthiophene derivatives for use as p38 map kinase inhibitors in the treatment of inflammatory diseases | ASTEX THERAPEUTICS LIMITED (GB) | 2007-04-12 | — | — | US | disclosed |
| EP-1040108-B1 | ORTHO-ANTHRANILAMIDE DERIVATIVES AS ANTI-COAGULANTS | SCHERING AG (DE) | 2004-02-25 | — | — | EP | disclosed |
| US-6498185-B1 | ENZYME FACTOR XA INHIBITORS | BERLEX LABORATORIES, INC. | 2002-12-24 | — | — | US | disclosed |
| US-6498185-B1 | ENZYME FACTOR XA INHIBITORS | BERLEX LABORATORIES, INC. | 2002-12-24 | — | — | US | disclosed |
| US-6380221-B1 | FOR THERAPY OF DISEASE-STATES CHARACTERIZED BY THROMBOTIC ACTIVITY | BERLEX LABORATORIES, INC. | 2002-04-30 | — | — | US | disclosed |
| US-6380221-B1 | FOR THERAPY OF DISEASE-STATES CHARACTERIZED BY THROMBOTIC ACTIVITY | BERLEX LABORATORIES, INC. | 2002-04-30 | — | — | US | disclosed |
| US-6140351-A | FOR TREATING THROMBOSIS | BERLEX LABORATORIES, INC. (US) | 2000-10-31 | — | — | US | disclosed |
| US-6140351-A | FOR TREATING THROMBOSIS | BERLEX LABORATORIES, INC. (US) | 2000-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182852-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | AURKA, AURKC, AURKB | CYP3A4 4332/4885ALOX15 4743/4885SMN1; SMN2 4359/4885 |
| US-20070082898-A1 | 5 Amino-2-carbonylthiophene derivatives for use as p38 map kinase inhibitors in the treatment of inflammatory diseases | CNKSR1, NOX5, NOX1 | CYP3A4 1790/4885ALOX15 471/4885SMN1; SMN2 2683/4885 |
| US-20100016318-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | AURKA, AURKC, AURKB | CYP3A4 4296/4885ALOX15 4703/4885SMN1; SMN2 4282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.